We are international

The 55th Annual Meeting of the American Society of Hematology (ASH) took place at the Ernest N. Morial Convention Center, New Orleans, LA from December 7-10, 2013.

The webcasts taped at the meeting are reports on the current status of some of the most interesting research in myeloma. Please be aware that at the time of posting, in some cases, the interviewees are reporting on interim data from incomplete clinical trials. Therefore not all the data presented are final results, and it is possible that results will be different when the data has matured with long-term follow-up. None of this research has yet been peer-reviewed and published in a medical journal.

Social Media Team
Immunomodulatory Agents
Proteasome Inhibitors
Minimal Residual Disease
Other Novel Agents
ASH 2013: Dr. Morie Gertz's Overview

Morie Gertz, MD, MACP
Roland Seidler Jr. Professor and Chair Department of Medicine, College of Medicine, 
Mayo Clinic, Rochester, MN, USA

ASH 2013: Dr. Ken Anderson's Overview

Ken Anderson, MD
Dana Farber Cancer Institute
Boston, Massachusetts

ASH 2013: Dr. Ola Landgren's Overview

Ola Landgren, MD, PHD
Multiple Myeloma Section
National Cancer Institute, National Institutes of Health
Bethesda, MD, USA

ASH 2013: Dr. Shaji Kumar's Overview

Shaji Kumar, MD
Professor of Medicine, Division of Hematology
Mayo Clinic, Rochester, MN

ASH 2013: Where we are currently with myeloma drugs HDAC 6, CD-38, ARRY 520, bendamustine, and panobinostat

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA, USA


ASH 2013: Current Status of Molecular Testing in Myeloma

Wee-Joo Chng, M.D.
National University Health System

ASH 2013: CRD Therapy in Both Smoldering Myeloma and Newly Diagnosed in Three Abstracts

Ola Landgren, MD
National Cancer Institute
Bethesda, MD, USA